SE0102888D0 - New formulation - Google Patents

New formulation

Info

Publication number
SE0102888D0
SE0102888D0 SE0102888A SE0102888A SE0102888D0 SE 0102888 D0 SE0102888 D0 SE 0102888D0 SE 0102888 A SE0102888 A SE 0102888A SE 0102888 A SE0102888 A SE 0102888A SE 0102888 D0 SE0102888 D0 SE 0102888D0
Authority
SE
Sweden
Prior art keywords
dosage form
relates
prevention
active substance
treatment
Prior art date
Application number
SE0102888A
Other languages
English (en)
Inventor
Karin Ellstroem
Ulf Kjellberg
Haakan Nyquist
Anders Ringberg
Annika Schweighofer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0102888A priority Critical patent/SE0102888D0/sv
Publication of SE0102888D0 publication Critical patent/SE0102888D0/sv
Priority to PCT/SE2002/001542 priority patent/WO2003017984A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
SE0102888A 2001-08-29 2001-08-29 New formulation SE0102888D0 (sv)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0102888A SE0102888D0 (sv) 2001-08-29 2001-08-29 New formulation
PCT/SE2002/001542 WO2003017984A1 (en) 2001-08-29 2002-08-28 A new extended release oral dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102888A SE0102888D0 (sv) 2001-08-29 2001-08-29 New formulation

Publications (1)

Publication Number Publication Date
SE0102888D0 true SE0102888D0 (sv) 2001-08-29

Family

ID=20285179

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102888A SE0102888D0 (sv) 2001-08-29 2001-08-29 New formulation

Country Status (2)

Country Link
SE (1) SE0102888D0 (sv)
WO (1) WO2003017984A1 (sv)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
AU2007254215A1 (en) * 2006-05-19 2007-11-29 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of viral infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
GB8624213D0 (en) * 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
SE510305C2 (sv) * 1997-05-30 1999-05-10 Astra Ab Nytt salt
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief

Also Published As

Publication number Publication date
WO2003017984A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
DK1256339T3 (da) Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
IS6970A (is) Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP
HK1068606A1 (en) Novel aminobenzoephenones
HUP0203716A2 (hu) Tumorellenes hatású szubsztituált (N-benzil-indol-3-il)-glioxilsav-származékok, ezeket tartalmazó gyógyszerkészítmények
SE0102440D0 (sv) New compound
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
SE0102887D0 (sv) New formulation
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
HUP0204391A2 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
SE0102888D0 (sv) New formulation
SE9702066D0 (sv) A new salt
SE0102886D0 (sv) New formulation
TW200502002A (en) A new oral immediated release dosage form
HUP0301408A2 (hu) Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására
DE60221104D1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure
SE0002354D0 (sv) New formulation
MX2022006535A (es) Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia.